期刊论文

【摘要】

The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested.

【授权许可】

CC BY
© The Author(s) 2017

【预览】

附件列表
Files	Size	Format	View
RO202311102133215ZK.pdf	1243KB	PDF	download

【参考文献】

[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]
[53]
[54]
[55]
[56]
[57]
[58]
[59]
[60]
[61]
[62]
[63]
[64]
[65]
[66]
[67]
[68]
[69]
[70]
[71]
[72]
[73]
[74]
[75]
[76]
[77]
[78]

Malaria Journal
Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway
Review
Carlos Chaccour¹ N. Regina Rabinovich²
[1] ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain;Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique;Instituto de Salud Tropical Universidad de Navarra, Pamplona, Spain;ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain;Harvard T.H. Chan School of Public Health, Boston, MA, USA;
关键词: Ivermectin; Endectocide; Clinical trials; Clinical development; Anopheles;
DOI : 10.1186/s12936-017-1802-3
received in 2017-01-09, accepted in 2017-04-06, 发布年份 2017
来源: Springer
PDF


	文献评价指标
	下载次数：0次	浏览次数：0次

【 摘 要 】

【 授权许可】

【 预 览 】

【 参考文献 】

【摘要】

【授权许可】

【预览】

【参考文献】